SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive P...( SciQuest Solution Enables Enhanced...)

SciQuest Solution Enables Enhanced Productivity and Decreased Expenses

CARY, N.C., June 25 /PRNewswire/ -- SciQuest, Inc., the global leader in helping academic, healthcare and research-centric organizations realize the potential of strategic procurement, today announced that BioMarin Pharmaceutical Inc., a leading biopharmaceutical research and development firm, has chosen the SciQuest eprocurement platform to streamline and enhance procurement functions for its operations in Novato, Calif.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, delivering first-to-market therapeutic treatments to patients with rare genetic disorders. The company's portfolio comprises three FDA-approved products and multiple clinical and preclinical product candidates.

"SciQuest's solution is extremely intuitive and allows our employees to manage and acquire their own materials and supplies quickly and easily," said Isaac Young, director of Supply Chain Operations for BioMarin. "This allows our employees to be more efficient and allows them to focus their efforts on our core business activities."

BioMarin uses SciQuest's SelectSite(TM) Express platform to maximize procurement cost savings and streamline the procurement process. SciQuest provides clear visibility into the progress of BioMarin's purchases through each step of the approval process. SciQuest then seamlessly integrates with BioMarin's ERP infrastructure for accounting and order tracking purposes.

For BioMarin, SciQuest's clear and demonstrated ROI, coupled with its industry-leading easy-to-use interface made it the solution of choice for its employees to handle their own procurement needs.

"SciQuest enables life sciences organizations to perform more effectively by ensuring that staff can quickly procure essential materials so that they can remain focused on developing new treatments," said Stephen Wiehe, president an
'/>"/>